PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
January 08, 2024 08:55 ET
|
PharmAla Biotech
PharmAla announces that its novel P1 molecule has been accepted by USPTO to its accelerated "Patent Prosecution Highway"
MAPS Welcomes New Investors, Name Change for MAPS Public Benefit Corporation
January 05, 2024 08:01 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS shares ownership of Lykos with mission-aligned investors, will continue to advance psychedelic research, change drug policy, and shape culture
Optimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage Formats
January 03, 2024 07:30 ET
|
Optimi Health Corp.
Optimi Health Granted Precursor Licence for 3,4-Methylenedioxyphenyl-2-propanone (“MDP2P”), the precursor used in the chemical synthesis of MDMA.
PharmAla Files Audited Financials for Year Ending August 31, 2023
December 29, 2023 16:00 ET
|
PharmAla Biotech
PharmAla releases audited year-end financials for the period ended August 31st.
MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD
December 13, 2023 18:16 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
The first NDA submission for any psychedelic-assisted therapy has been submitted through a 30-year effort initiated and led by the nonprofit MAPS
Optimi Health and Sunshine Earth Labs Ltd. Forge Strategic Supply Agreement
December 07, 2023 07:30 ET
|
Optimi Health Corp.
Optimi Health and Sunshine Earth Labs Ltd. Forge Strategic Supply Agreement
Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing
November 28, 2023 07:42 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health...
PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules
November 15, 2023 08:55 ET
|
PharmAla Biotech
PharmAla Biotech contracted with Filament Health to manufacture a second batch of MDMA capsules; manufacturing is complete and shipped to clients.
World’s First Observational Trial to Assess Real-World Efficacy of MDMA Treatment
November 09, 2023 08:55 ET
|
PharmAla Biotech
PharmAla partners with Heroic Hearts Canada and the University of Calgary to launch the world's first observational rial into MDMA's real-world efficacy
Canadian Psychedelic Trade Association Endorses Senate Report Calling for Research into Psychedelic-Assisted Therapy
November 08, 2023 16:50 ET
|
Psychedelics Canada
PsyCan Endorses Senate Report into Psychedelic Treatments for Veterans